Studies
Registries follow patients through years of real-world care and anchor the consortium's research beyond interventional trials. The PCCTC operates the IRONMAN and PROMISE registries and is extending the model to colorectal, breast, and lung cancer.
An international registry for men with advanced prostate cancer. Five PCCTC-run substudies have been built on its platform, reusing its sites, contracts, and data pipelines.
A PCCTC-managed registry linking germline genetics to outcomes and treatment effectiveness for patients with prostate cancer.
A PCCTC-managed registry program extending the IRONMAN and PROMISE model to colorectal, breast, and lung cancer on the same coordinated infrastructure.
The model
A PCCTC registry doubles as a real-world evidence research platform. These platforms enable both prospective sub-studies and retrospective data analyses, leveraging existing sites, contracts and data pipelines to answer new questions without standing up new study infrastructure.
The same teams that run the PCCTC's interventional trials operate every registry program, ensuring our real-world datasets are as robust as those collected for prospective clinical trials.
PRODIGY: Observational study to describe effectiveness of olaparib in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and carry selected homologous recombination repair gene mutations
EMPRO: Engaging Men in Patient Reported Outcomes
BIOGUARD: BIOmarker landscape in GU cancers: Assessment in the Real-worlD
IRONSeq: Characterizing the whole genome landscape of the IRONMAN Registry
Talk with our team about registry design, operations, and nested substudies.